H1B Salary Data

Home › Employers › Escalante Biosciences, Inc.

Escalante Biosciences, Inc.: H-1B salaries and sponsorship

Escalante Biosciences, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $120,000.

Applications (LCAs)3
Certified3
Employer addressSan Francisco, CA
H-1B dependent employerNo
Median offered salary$120,000
Middle half of salaries$120,000–$142,500
10th–90th percentile$120,000–$156,000

Does Escalante Biosciences, Inc. sponsor H-1B visas?

Escalante Biosciences, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on May 27, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Senior Research Associate1$120,000
Machine Learning Scientist1$165,000
Research Associate1$120,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20241$120,000
FY20262$142,500

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Research Associate$120,000
Level II
San Francisco, CAMay 27, 2026Jun 20, 2026Certified
Machine Learning Scientist$165,000
Level III
San Francisco, CAApr 6, 2026Oct 1, 2026Certified
Senior Research Associate$120,000
Level II
San Francisco, CAJun 26, 2024Jul 22, 2024Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).